China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $111.67 for the company and are anticipating that the company will post $1.11 earnings per share for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 161 out of 265 based on the ratings given to related companies.
A number of equities research analysts have recently weighed in on the company. BidaskClub raised China Biologic Products from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 20th. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th.
Several institutional investors and hedge funds have recently bought and sold shares of CBPO. Legal & General Group Plc raised its stake in shares of China Biologic Products by 41.2% during the 3rd quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock worth $274,000 after purchasing an additional 865 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of China Biologic Products by 73.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 1,952 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of China Biologic Products during the 3rd quarter worth about $439,000. Strs Ohio purchased a new stake in shares of China Biologic Products during the 3rd quarter worth about $664,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of China Biologic Products during the 3rd quarter worth about $795,000. 65.13% of the stock is owned by institutional investors.
Shares of China Biologic Products (NASDAQ:CBPO) traded up $3.87 during trading on Friday, reaching $81.37. The company had a trading volume of 198,181 shares, compared to its average volume of 183,053. China Biologic Products has a 1 year low of $72.21 and a 1 year high of $120.46. The stock has a market cap of $2,570.00, a P/E ratio of 21.19, a P/E/G ratio of 0.98 and a beta of 1.79.
WARNING: “Brokerages Anticipate China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 EPS” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/brokerages-anticipate-china-biologic-products-holdings-inc-cbpo-to-post-1-11-eps.html.
China Biologic Products Company Profile
Get a free copy of the Zacks research report on China Biologic Products (CBPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.